Picture of Aelis Farma SA logo

AELIS Aelis Farma SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareBalancedSmall CapNeutral

Momentum

Relative Strength (%)
1m-2.16%
3m-5.49%
6m-12.3%
1yr-17.85%
Volume Change (%)
10d/3m-21.98%
Price vs... (%)
52w High-4.95%
50d MA+0.37%
200d MA-0.83%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)7.37
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value10.37
Price to Tang. Book10.49
Price to Free Cashflown/a
Price to Sales31.93
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-30.85%
Return on Equity-27.17%
Operating Margin-113.9%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Aelis Farma SA EPS forecast chart

Profile Summary

Aelis Farma SA is a France-based company that is specialized in the research and development of drugs for the treatment of disorders of Central Nervous System (CNS). The Company provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). It offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. It provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The Company operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    June 30th, 2023
    Incorporated
    October 3rd, 2013
    Public Since
    February 18th, 2022
    No. of Employees
    22
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    fr flag iconEuronext - Paris
    Shares in Issue
    13,183,362

    AELIS Share Price Performance

    Upcoming Events for AELIS

    Aelis Farma SA Annual Shareholders Meeting

    Similar to AELIS

    Picture of AB Science SA logo

    AB Science SA

    fr flag iconEuronext - Paris

    Picture of Advicenne SA logo

    Advicenne SA

    fr flag iconEuronext - Paris

    Picture of Boiron SA logo

    Boiron SA

    fr flag iconEuronext - Paris

    Picture of DBV Technologies SA logo

    DBV Technologies SA

    fr flag iconEuronext - Paris

    Picture of Elsalys Biotech SA logo

    Elsalys Biotech SA

    fr flag iconEuronext - Paris

    FAQ